Search
Design Therapeutics Inc
DSGNAdd to Watchlist
12.180USD
-0.440-3.49%
Close 07-31 16:00（ET）Quotes delayed by 15 min
760.73MMarket Cap
LossP/E TTM
More Details of Design Therapeutics Inc Company
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Design Therapeutics Inc Info
Ticker SymbolDSGN
Company nameDesign Therapeutics Inc
IPO dateMar 26, 2021
CEOShah (Pratik)
Number of employees54
Security typeOrdinary Share
Fiscal year-endMar 26
Address6005 Hidden Valley Road
CityCARLSBAD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92011
Phone18582934900
Websitehttps://www.designtx.com/
Ticker SymbolDSGN
IPO dateMar 26, 2021
CEOShah (Pratik)
Company Executives of Design Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Dr. Sean Jeffries, Ph.D.
Dr. Sean Jeffries, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Christopher M. (Chris) Storgard, M.D.
Dr. Christopher M. (Chris) Storgard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Justin Gover
Mr. Justin Gover
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Dr. Sean Jeffries, Ph.D.
Dr. Sean Jeffries, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
FAQs
Who are the top five shareholders of Design Therapeutics Inc?
The top five shareholders of Design Therapeutics Inc are: Dr. Rodney W. Lappe, Ph.D.
How many institutions hold shares of Design Therapeutics Inc (DSGN)?
As of 2026Q1, 222 institutions hold shares of Design Therapeutics Inc, with a combined market value of approximately 38.66M, accounting for 61.89% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 688602.00.